Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 4, 2004, Pages 623-628

  Ingerslev, J ^a   Jankowski, M A ^b   Weston, S B ^b   Charles, L A ^c   Bader, Rosella ^d   Bohn, Sandy ^e   Meyer, Karen ^e   Bovill, E G ^f   Golden, Elizabeth ^f   Budde, Ulrich ^g   Burgess, Clive ^h   Caron, Claudine ⁱ   Dunnington, Paula ^j   Flanders, Michele ^k   Germain, Lorna ^l   Hoots, Keith ^m   Sayre, D ^m   Larsen, H ^a   Johns, Cindy ⁿ   Joist, H ^o   Chance, D ^o   Hoernig, Lynn ^p   Meyer, Judith ^q   Monteagudo, J ^r   Needham, Jane ^s   Negrier, Claude ^t   Nightingale, Joanna ^u   Oswaldsson, Ulla ^v   Peerschke, E ^w   Castellone, Donna ^w   McCraw, Angus ^x   Riddell, Anne ^x   Kitchen, S ^y   Sampson, B ^y   Scharrer, Inge ^z   Shima, Midora ^aa   Tusell, Joan ^ab   Warren, Janis ^ac   Weber, Lisa ^ad   Lusher, Jean ^ae   Wiseman, Carol R ^ae   Quinlan, Angela ^af   Stang, Linda ^ag   more..

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b PFIZER INC   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Centro Emofilia e Trombosi   (Italy)

^e UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^f FLETCHER ALLEN HEALTH CARE   (United States)

^g Labor Prof Arndt and Partner   (Germany)

^h GREAT ORMOND STREET HOSPITAL   (United Kingdom)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^k ARUP LABORATORIES   (United States)

^l ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^m UNIVERSITY OF TEXAS   (United States)

ⁿ Esoterix Inc   (United States)

^o SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

^p CHILDREN S HOSPITAL OF BUFFALO   (United States)

^q CHILDREN S HOSPITAL OAKLAND   (United States)

^r HOSPITAL CLÍNIC   (Spain)

^s NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^t EDOUARD HERRIOT HOSPITAL   (France)

^u KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^v BIOVITRUM AB   (Sweden)

^w NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^x ROYAL FREE HOSPITAL   (United Kingdom)

^y ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^z UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^aa NARA MEDICAL UNIVERSITY   (Japan)

^ab HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

^ac LEICESTER ROYAL INFIRMARY   (United Kingdom)

^ad Leicester Royal Infirmary ^*  (United States)

^ae Children's Hospital of Michigan   (United States)

^af CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^ag UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

more..

Author keywords

Assay discrepancies; Recombinant B domain deleted FVIII; Standardization

Indexed keywords

B DOMAIN DELETED RECOMBINANT BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 CONCENTRATE; UNCLASSIFIED DRUG; B DOMAIN DELETED FACTOR VIII; B-DOMAIN-DELETED FACTOR VIII; BLOOD CLOTTING FACTOR 8; CHROMOGENIC SUBSTRATE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; PEPTIDE FRAGMENT;

ACCURACY; ANALYTIC METHOD; ARTICLE; ASSAY; BLOOD CLOTTING; CALIBRATOR; DISEASE SEVERITY; HEMOPHILIA; HUMAN; LABORATORY TEST; PLASMA; PRIORITY JOURNAL; STANDARDIZATION; BLOOD; COMPARATIVE STUDY; HEMOPHILIA A; OBSERVER VARIATION; PARTIAL THROMBOPLASTIN TIME; STANDARD;

BLOOD COAGULATION; CHROMOGENIC COMPOUNDS; FACTOR VIII; HEMOPHILIA A; HUMANS; INDICATORS AND REAGENTS; OBSERVER VARIATION; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; REFERENCE STANDARDS;

EID: 4844226443     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00657.x     Document Type: Article

References (13)

1. Mikaelsson M, Oswaldsson U, Jankowski M. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38 (Suppl. 4): 13-23.
2. Factor VIII and Factor IX Scientific Subcommittee of the SSC reports, 2001 http://www.med.unc.edu/isth/01sscminutes/01factviiifactix.html and 2002 http://www.med.unc.edu/isth/02sscminutes/02factviiifactix.html
3. Barrowcliffe TW. Factor VIII and Factor IX Sub-committee Recommendations for the assay of high-purity factor VIII concentrates. Thromb Haemost 1993; 70: 876-7.
4. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
5. Hubbard A, Weller L, Beven S. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haematol 2002; 117: 247-54.
6. Barrowcliffe TW, Mertens K, Preston FE, Ingerslev J. Laboratory aspects of haemophilia therapy. Haemophilia 2002; 8 244-9.
7. Lee CA, Barrowcliffe TW, Bray G, Gomperts E, Hubbard A, Kemball-Cook G, Lilley P, Owens D, Von Tilberg L, Pasi J. Pharmacokinetic in-vivo comparison using one-stage and chromogenic substrate assays with two formulations of Hemofil-M. Thromb Haemost 1996; 76: 950-6.
8. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity - assay discrepancies. Haemophilia 1998: 4: 641-5.
9. Lee CA, Owens GB, Giangrande P, Collins P, Hay C, Gomperts E, Schroth P, Barrowcliffe T. Pharmacokinetics of recombinant factor VIII (Recombinate®) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost 1999; 82: 1644-7.
10. Hubbard A, Weller L, Bevan A. Activation profiles of factor VIII in concentrates reflect one-stage/chromogenic potency discrepancies. Br J Haematol 2002; 117: 957-60.
11. Mcintosh JH, Owens D, Lee CA, Raut S, Barrowcliffe TW. A modified thrombin generation test for the measurement of factor VIII concentrates. J Thromb Haemost 2003; 1: 1005-11.
12. Barrowcliffe TW, Raut S, Hubbard AR. Discrepancies in potency assessment of recombinant FVIII concentrates. Hemophilia 1998; 4 634-40.
13. Weston S, Jankowski M, Komusin P. Optimization of factor VIII clotting assays: evaluation of VWF content in FVIII deficient plasma and effect of albumin in dilution buffer. J Thromb Haemost 2003; 1 (Suppl. 1): P1617.